ArticleDiscover oncology2025
Cuproptosis-related gene DLD expression correlates with the prognosis and tumor immune microenvironment in clear cell renal cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundCuproptosis, or copper-induced programmed cell death, shows promise in cancer therapy. However, the role of the copper-related gene dihydrofatty acyl dehydrogenase (DLD) in the prognosis of renal clear cell carcinoma (KIRC) remains unclear.
methodsRaw data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were analyzed using R. DLD expression in cancer was evaluated through these databases, and its correlation with tumor immunological features was assessed using the TIMER and TISIDB databases.
resultThe results demonstrated that DLD is downregulated in KIRC, providing diagnostic and prognostic value. Cox regression identified DLD expression as a protective factor. GO and KEGG analyses revealed DLD-associated gene pathways, while its expression correlated with immune cell infiltration and marker expression in KIRC.
conclusionOur findings highlight DLD's predictive value in KIRC and its role in the tumor microenvironment. As a diagnostic and prognostic marker, DLD offers potential for identifying therapeutic targets and enhancing KIRC immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.